| Recruiting | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic NCT06998940 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX C NCT07409272 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Enrolling By Invitation | Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate NCT07344220 | Hoag Memorial Hospital Presbyterian | Phase 2 |
| Recruiting | BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and R NCT07226856 | Mayo Clinic | Phase 2 |
| Recruiting | Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced a NCT07076212 | Medical University of South Carolina | Phase 2 |
| Recruiting | TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, NCT07189195 | University of California, Davis | Phase 1 |
| Active Not Recruiting | A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer NCT06396091 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Withdrawn | TCR1020-CD8 T Cells in KRAS-mutated Cancers NCT06707896 | University of Pennsylvania | Phase 1 |
| Recruiting | Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fie NCT06576115 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Recruiting | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally A NCT06381154 | Mayo Clinic | Phase 2 |
| Recruiting | Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and The NCT06524973 | City of Hope Medical Center | N/A |
| Active Not Recruiting | Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer NCT06018883 | Fudan University | Phase 3 |
| Recruiting | Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma NCT06229496 | Chang Gung Memorial Hospital | Phase 1 |
| Terminated | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreat NCT04975516 | Mayo Clinic | Phase 2 |
| Withdrawn | Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the NCT05926206 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Terminated | A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenoca NCT05484011 | HiberCell, Inc. | Phase 1 |
| Active Not Recruiting | Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Aden NCT05102721 | Vaccinex Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) NCT05642962 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma NCT05249101 | CG Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer NCT05034627 | OHSU Knight Cancer Institute | Phase 1 |
| Terminated | FOLFIRINOX + NIS793 in Pancreatic Cancer NCT05417386 | Colin D. Weekes, M.D., PhD | Phase 1 |
| Completed | A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced NCT05383352 | Ipsen | Phase 1 |
| Completed | Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer NCT05078775 | Faeth Therapeutics | N/A |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumor NCT04514497 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patie NCT04787991 | Cancer Insight, LLC | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea NCT04616534 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma NCT04387071 | University of Southern California | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients NCT04548752 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation NCT03608631 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. NCT04348045 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Unknown | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab NCT04652206 | Scandion Oncology A/S | Phase 1 / Phase 2 |
| Completed | Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic NCT04524702 | Emory University | Phase 2 |
| Active Not Recruiting | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Lipo NCT04233866 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Recruiting | Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pan NCT04115163 | Anne Noonan | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer NCT04058964 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer NCT04229004 | Pancreatic Cancer Action Network | Phase 3 |
| Completed | Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer NCT04191421 | Emory University | Phase 1 / Phase 2 |
| Completed | Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer NCT04132505 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreat NCT04050085 | University of California, Davis | Phase 1 |
| Terminated | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors NCT02757391 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarc NCT03974854 | Centre Hospitalier Universitaire de Besancon | Phase 2 |
| Completed | Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adeno NCT03943667 | UNICANCER | Phase 3 |
| Completed | Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer NCT03910387 | Emory University | Phase 2 |
| Active Not Recruiting | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer NCT03816163 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Active Not Recruiting | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pan NCT03337087 | Academic and Community Cancer Research United | Phase 1 / Phase 2 |
| Completed | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. NCT03611556 | MedImmune LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder C NCT03257761 | University of Southern California | Phase 1 |
| Completed | Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas NCT03006302 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | TAS102 in Combination With NAL-IRI in Advanced GI Cancers NCT03368963 | Emory University | Phase 1 / Phase 2 |
| Completed | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic NCT03331562 | Translational Genomics Research Institute | Phase 2 |
| Active Not Recruiting | BATs Treatment for Pancreatic Cancer, Phase Ib/II NCT03269526 | University of Virginia | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With NCT03214250 | Parker Institute for Cancer Immunotherapy | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer NCT03095781 | Emory University | Phase 1 |
| Completed | LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy NCT02985125 | Georgetown University | Phase 1 / Phase 2 |
| Completed | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer NCT02847000 | Yogen Saunthararajah | EARLY_Phase 1 |
| Completed | Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer NCT02907099 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Olaparib in Treating Patients With Stage IV Pancreatic Cancer NCT02677038 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreat NCT02890355 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cance NCT02826486 | BioLineRx, Ltd. | Phase 2 |
| Active Not Recruiting | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors NCT02498613 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer NCT02383433 | Case Comprehensive Cancer Center | Phase 2 |
| Withdrawn | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery an NCT02567396 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer NCT02671890 | Mayo Clinic | Phase 1 |
| Terminated | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro NCT02650635 | Mayo Clinic | Phase 1 |
| Completed | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer NCT02620865 | Barbara Ann Karmanos Cancer Institute | Phase 1 / Phase 2 |
| Completed | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer NCT02562898 | Margaret Tempero | Phase 1 / Phase 2 |
| Active Not Recruiting | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or NCT02495896 | University of Southern California | Phase 1 |
| Completed | Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreat NCT02504333 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Phase 1 / Phase 2 |
| Completed | Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment NCT02436668 | Pharmacyclics LLC. | Phase 3 |
| Completed | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metas NCT02324543 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Completed | Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or NCT02227940 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer NCT02333188 | University of Chicago | Phase 1 |
| Completed | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhi NCT02194829 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer NCT02231723 | Sumitomo Pharma America, Inc. | Phase 1 |
| Completed | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreat NCT02077881 | NewLink Genetics Corporation | Phase 1 / Phase 2 |
| Completed | A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects NCT02048384 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Recruiting | Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer NCT01954992 | Eleison Pharmaceuticals LLC. | Phase 3 |
| Completed | Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma NCT02117258 | Zeria Pharmaceutical | Phase 2 |
| Completed | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer NCT01959139 | SWOG Cancer Research Network | Phase 1 / Phase 2 |
| Completed | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients W NCT02045589 | Theriva Biologics SL | Phase 1 |
| Withdrawn | Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer NCT01830322 | Cornerstone Pharmaceuticals | Phase 2 |
| Completed | FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer NCT01896869 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. NCT01964287 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 1 / Phase 2 |
| Completed | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer NCT01825603 | University of Nebraska | Phase 1 |
| Terminated | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors NCT01562899 | Pfizer | Phase 1 / Phase 2 |
| Active Not Recruiting | Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer NCT01660971 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer NCT01729481 | Ludwig-Maximilians - University of Munich | Phase 2 |
| Active Not Recruiting | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With NCT01585805 | National Cancer Institute (NCI) | Phase 2 |
| Completed | The Study of Metastatic Pancreatic Adenocarcinoma NCT01415713 | National Health Research Institutes, Taiwan | Phase 1 / Phase 2 |
| Withdrawn | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Th NCT01510561 | Gilead Sciences | Phase 1 |
| Terminated | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol NCT01760252 | Beth Israel Medical Center | Phase 2 |
| Completed | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer NCT01360853 | Traws Pharma, Inc. | Phase 3 |
| Completed | Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Ad NCT01233375 | Clovis Oncology, Inc. | Phase 2 |
| Completed | Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma NCT01204372 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 2 |
| Completed | A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenoc NCT01124786 | Clovis Oncology, Inc. | Phase 2 |
| Completed | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma NCT00998322 | Oncolytics Biotech | Phase 2 |
| Withdrawn | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic P NCT02575508 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |